About Eli Lilly and Company
Eli Lilly is a leading pharmaceutical company that develops depression, endocrinology, oncology, and cardiovascular care medicines. Its top-selling drugs include Cymbalta for depression and pain, Alimta for lung cancer, Humalog and Humulin insulin for diabetes, and Cialis for erectile dysfunction. Lilly also makes medications to treat schizophrenia and bipolar disorder (Zyprexa), osteoporosis (Forteo), ADHD (Strattera), gastric and lung cancer (Cyramza), and diabetes (Jardiance and Trulicity). The company, which has around 10 production and distribution facilities in about 10 countries, generates most of its revenue in the US.
Lilly has been around for more than 140 years and, unlike many other drug companies, has kept its operations focused almost exclusively on the task of pharmaceutical manufacturing. The company operates in a single business segment, Human pharmaceutical products.
Lilly's revenue is generated from its products. Its largest product is Trucility, which accounts for almost 20% of total revenue, followed by Humalog for nearly 15%. Both products are treatment for diabetes.
Alimta, a treatment for non-small lung cancer, accounts for almost 10% of total revenue. The remaining revenues are generated from: Forteo, Taltz, Humulin, Basaglar, Jardiance, Cyramza, Cialis, Cymbalta, Traienta, Verzenio, Erbitux, Olumniant, Zyprexa, Strattera, Emgality and other products.
Lilly, based in Indianapolis, Indiana, sells its products in approximately 120 countries, with the US market accounting for over 55% of sales. Europe accounts for more than 15% of sales and Japan accounts for over 10%. The remaining sales are generated from other foreign countries (about 15%).
The company operates research, manufacturing, and distribution facilities in the US, Europe, Asia, Australia, and the Americas. It owns almost 10 production and distribution sites in the US and Puerto Rico; major production sites are in Indianapolis, Indiana; Branchburg, New Jersey; and Carolina, Puerto Rico. Lilly's major international production sites are in Ireland, the UK, France, Italy, Spain, and China.
Altogether, Lilly conducts R&D in about five countries.
Sales and Marketing
In the US, Lilly's products are promoted to physicians, hospitals, and pharmacies through direct sales representatives and contract sales organizations. Products are distributed through independent wholesalers, primarily AmerisourceBergen, Cardinal Health, and McKesson. These three distributors each account for between 10% and 20% of sales. Internationally, the company uses a direct sales force in most markets, though it occasionally markets products through independent distributors. It also partners with other pharmaceuticals to market its products.
Lilly's advertising expenses totaled $1.1 billion, $900 million and $700 million for the years 2019, 2018 and 2017, respectively.
Lilly has reported higher revenue for five straight years by rolling out a steady stream of new drugs. Except for a loss in 2017, net income continues its upward trend for the same period.
In 2019, revenue rose 4% to $24.5 billion, up about $826.2 million from 2018 driven by increased volume, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates.
Lilly posted $8.3 billion in net income in 2019, its best showing in five years. The 2019 increase was primarily driven by a gain of approximately $3.7 billion related to the disposition of Elanco.
Lilly's coffers held $2.3 billion in cash and equivalents at the end of 2019 compared to $8 billion at the 2018 year-end. In 2019, operations produced $4.8 billion, but investing activities used $8.1 billion for acquisitions and purchases of property and equipment. Financing activities used another $200 million.
Eli Lilly strategically invests in external research and technologies that it believes to complement and strengthen its own efforts. These investments can take many forms, including licensing arrangements, collaborations, and acquisitions. The company views its business development activity as an important way to achieve its strategies, as the company seeks to bolster its pipeline and enhance shareholder value. The company continues to evaluate business development transactions that have the potential to strengthen their business.
In January 2020, Eli Lilly announced an agreement to acquire Dermira, Inc. for a purchase price of approximately $1.1 billion. The acquisition will expand their immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase III clinical development program for the treatment of moderate-to-severe atopic dermatitis.
Mergers and Acquisitions
Acquisitions are one key way in which Lilly boosts its development pipeline.
In early 2020, Lilly acquired Dermira, Inc, for $1.1 billion. Dermira, based in California, is a biopharmaceutical company focused on bringing biotech ingenuity to medical dermatology for patients living with chronic skin conditions. The transaction will expand Lilly's immunology pipeline and its marketed dermatology medicines.
In early 2019 the company acquired Connecticut-based startup Loxo Oncology for $8 billion. Loxo's first commercial product, developed with Bayer, is cancer drug Vitrakvi. The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines through the addition of a pipeline of highly selective potential medicines for patients with genomically defined cancers.
1 Lilly Corporate Ctr
Indianapolis, IN 46285-0002
Phone: 1 (317) 276-2000
Employer Type: Publicly Owned
Stock Symbol: LLY
Stock Exchange: , NYSE
SVP and President, Diabetes Business Unit and Lilly USA: Enrique A. Conterno
Chairman: John C. Lechleiter
President and CEO: David A. Ricks
Employees (This Location): 4,000
Employees (All Locations): 33,625
Little Rock, AR
Newbury Park, CA
San Diego, CA
Fort Dodge, IA
Orland Park, IL
Terre Haute, IN
Saint Paul, MN
New Hyde Park, NY
Broken Arrow, OK
Aracoiaba Da Serra, Brazil